{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:46:57Z","timestamp":1793191617286,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005758","name":"Universit\u00e0 Politecnica delle Marche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005758","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40265-023-01936-y","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T14:02:26Z","timestamp":1694440946000},"page":"1409-1424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-0083","authenticated-orcid":false,"given":"Simona","family":"Lattanzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Del Giovane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Matricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Meletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam Tabaee","family":"Damavandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Silvestrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Brigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"issue":"Suppl. 2","key":"1936_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","volume":"52","author":"C Dravet","year":"2011","unstructured":"Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52(Suppl. 2):3\u20139.","journal-title":"Epilepsia"},{"key":"1936_CR2","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1212\/WNL.0000000000003716","volume":"88","author":"V Cetica","year":"2017","unstructured":"Cetica V, Chiari S, Mei D, Parrini E, Grisotto L, Marini C, et al. Clinical and genetic factors predicting Dravet syndrome in infants with SCN1A mutations. Neurology. 2017;88:1037\u201344.","journal-title":"Neurology"},{"issue":"Pt 11","key":"1936_CR3","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1113\/jphysiol.2010.187484","volume":"588","author":"WA Catterall","year":"2010","unstructured":"Catterall WA, Kalume F, Oakley JC. NaV1.1 channels and epilepsy. J Physiol. 2010;588(Pt 11):1849\u201359.","journal-title":"J Physiol"},{"key":"1936_CR4","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1111\/epi.17274","volume":"63","author":"EC Wirrell","year":"2022","unstructured":"Wirrell EC, Hood V, Knupp KG, Meskis MA, Nabbout R, Scheffer IE, Wilmshurst J, Sullivan J. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022;63:1761\u201377.","journal-title":"Epilepsia"},{"key":"1936_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.980937","volume":"13","author":"J Wu","year":"2022","unstructured":"Wu J, Zhang L, Zhou X, Wang J, Zheng X, Hu H, Wu D. Efficacy and safety of adjunctive antiseizure medications for Dravet syndrome: a systematic review and network meta-analysis. Front Pharmacol. 2022;13: 980937.","journal-title":"Front Pharmacol"},{"key":"1936_CR6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"1936_CR7","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: Higgins JPT, Green S, editors. The Cochrane Collaboration; 2011. http:\/\/handbook-5-1.cochrane.org\/. Accessed Mar 2023."},{"key":"1936_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, Salanti G. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17: e1003082.","journal-title":"PLoS Med"},{"key":"1936_CR9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"1936_CR10","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"1936_CR11","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","volume":"78","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, Silvestrini M. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs. 2018;78:1791\u2013804.","journal-title":"Drugs"},{"key":"1936_CR12","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40263-020-00759-9","volume":"34","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Trinka E, Zaccara G, Striano P, Del Giovane C, Silvestrini M, Brigo F. Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis. CNS Drugs. 2020;34:1105\u201320.","journal-title":"CNS Drugs"},{"key":"1936_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00415-017-8681-y","volume":"265","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Grillo E, Brigo F, Silvestrini M. Efficacy and safety of perampanel in Parkinson\u2019s disease. A systematic review with meta-analysis. J Neurol. 2018;265:733\u201340.","journal-title":"J Neurol"},{"key":"1936_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3:80\u201397.","journal-title":"Res Synth Methods"},{"key":"1936_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099682","volume":"9","author":"G Salanti","year":"2014","unstructured":"Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS ONE. 2014;9: e99682.","journal-title":"PLoS ONE"},{"key":"1936_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JP, Geddes JR, et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159:130\u20137.","journal-title":"Ann Intern Med"},{"key":"1936_CR17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/ije\/dys222","volume":"42","author":"AA Veroniki","year":"2013","unstructured":"Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013;42:332\u201345.","journal-title":"Int J Epidemiol"},{"key":"1936_CR18","unstructured":"European Medicines Agency. Committee for medicinal products for human use. Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-2_en.pdf. Accessed Mar 2023."},{"key":"1936_CR19","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A, Rey E, d\u2019Athis P, Vincent J, Dulac O, Pons G. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356:1638\u201342.","journal-title":"Lancet"},{"issue":"Suppl. 8","key":"1936_CR20","first-page":"155","volume":"43","author":"R Guerrini","year":"2002","unstructured":"Guerrini R, Tonnelier S, d\u2019Athis P, Rey E, Vincent J, Pons G, et al. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial. Epilepsia. 2002;43(Suppl. 8):155.","journal-title":"Epilepsia"},{"key":"1936_CR21","doi-asserted-by":"crossref","unstructured":"Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, et al.; GWPCARE1 Part A Study Group. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204\u201311.","DOI":"10.1212\/WNL.0000000000005254"},{"key":"1936_CR22","doi-asserted-by":"crossref","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al.; Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syn-drome. N Engl J Med. 2017;376:2011\u201320.","DOI":"10.1056\/NEJMoa1611618"},{"key":"1936_CR23","doi-asserted-by":"crossref","unstructured":"Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, Saneto RP, Checketts D, Dunayevich E, Knappertz V; GWPCARE2 Study Group. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial. JAMA Neurol. 2020;77:613\u201321.","DOI":"10.1001\/jamaneurol.2020.0073"},{"key":"1936_CR24","doi-asserted-by":"crossref","unstructured":"Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, Devinsky O, Cross JH, Guerrini R, Talwar D, Miller I, Farfel G, Galer BS, Gammaitoni A, Mistry A, Morrison G, Lock M, Agarwal A, Lai WW, Ceulemans B; FAiRE DS Study Group. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:2243\u201354.","DOI":"10.1016\/S0140-6736(19)32500-0"},{"key":"1936_CR25","doi-asserted-by":"crossref","unstructured":"Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, Stephani U, Laux L, Wirrell E, Knupp K, Chiron C, Farfel G, Galer BS, Morrison G, Lock M, Agarwal A, Auvin S; FAiRE, DS Study Group. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77:300\u201308.","DOI":"10.1001\/jamaneurol.2019.4113"},{"key":"1936_CR26","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1111\/epi.17367","volume":"63","author":"CD Hahn","year":"2022","unstructured":"Hahn CD, Jiang Y, Villanueva V, Zolnowska M, Arkilo D, Hsiao S, Asgharnejad M, Dlugos D. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA). Epilepsia. 2022;63:2671\u201383.","journal-title":"Epilepsia"},{"key":"1936_CR27","unstructured":"Center for Drug Evaluation and Research. Application number:206709Orig1s000, 207223Orig1s000. Clinical Reviews 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/206709Orig1s000,207223Orig1s000MedR.pdf. Accessed Mar 2023."},{"key":"1936_CR28","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). International non-proprietary name: stiripentol. Scientific Discussion. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/diacomit-epar-scientific-discussion_en.pdf. Accessed Mar 2023."},{"key":"1936_CR29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","volume":"12","author":"C Ibeas Bih","year":"2015","unstructured":"Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12:699\u2013730.","journal-title":"Neurotherapeutics"},{"key":"1936_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2022.114288","volume":"360","author":"A Del Pozo","year":"2023","unstructured":"Del Pozo A, Barker-Haliski M. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. Exp Neurol. 2023;360: 114288.","journal-title":"Exp Neurol"},{"key":"1936_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106989","volume":"105","author":"P Martin","year":"2020","unstructured":"Martin P, de Witte PAM, Maurice T, Gammaitoni A, Farfel G, Galer B. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav. 2020;105: 106989.","journal-title":"Epilepsy Behav"},{"key":"1936_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fphar.2017.00191","volume":"8","author":"J Sourbron","year":"2017","unstructured":"Sourbron J, Smolders I, de Witte P, Lagae L. Pharmacological analysis of the anti-epileptic mechanisms of fenfluramine in scn1a mutant zebrafish. Front Pharmacol. 2017;8:191.","journal-title":"Front Pharmacol"},{"key":"1936_CR33","doi-asserted-by":"publisher","first-page":"8416","DOI":"10.3390\/ijms22168416","volume":"22","author":"P Martin","year":"2021","unstructured":"Martin P, Reeder T, Sourbron J, de Witte PAM, Gammaitoni AR, Galer BS. An emerging role for sigma-1 receptors in the treatment of developmental and epileptic encephalopathies. Int J Mol Sci. 2021;22:8416.","journal-title":"Int J Mol Sci"},{"key":"1936_CR34","first-page":"1159","volume":"9","author":"D Samanta","year":"2022","unstructured":"Samanta D. Fenfluramine: a review of pharmacology, clinical efficacy, and safety in epilepsy. Children (Basel). 2022;9:1159.","journal-title":"Children (Basel)."},{"key":"1936_CR35","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/epi.17201","volume":"63","author":"V Riban","year":"2022","unstructured":"Riban V, Heulard I, Reversat L, Si Hocine H, Verleye M. Stiripentol inhibits spike-and-wave discharges in animal models of absence seizures: a new mechanism of action involving T-type calcium channels. Epilepsia. 2022;63:1200\u201310.","journal-title":"Epilepsia"},{"key":"1936_CR36","doi-asserted-by":"publisher","first-page":"17081","DOI":"10.1038\/s41598-020-74036-6","volume":"10","author":"T Nishi","year":"2020","unstructured":"Nishi T, Kondo S, Miyamoto M, Watanabe S, Hasegawa S, Kondo S, et al. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice. Sci Rep. 2020;10:17081.","journal-title":"Sci Rep"},{"key":"1936_CR37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40263-020-00708-6","volume":"34","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Brigo F, Trinka E, Zaccara G, Striano P, Del Giovane C, Silvestrini M. Adjunctive cannabidiol in patients with dravet syndrome: a systematic review and meta-analysis of efficacy and safety. CNS Drugs. 2020;34:229\u201341.","journal-title":"CNS Drugs"},{"key":"1936_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/14737175.2021.1834383","volume":"21","author":"S Lattanzi","year":"2021","unstructured":"Lattanzi S, Zaccara G, Russo E, La Neve A, Lodi MAM, Striano P. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome. Expert Rev Neurother. 2021;21:99\u2013110.","journal-title":"Expert Rev Neurother"},{"key":"1936_CR39","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40120-023-00452-1","volume":"12","author":"P Tabaee Damavandi","year":"2023","unstructured":"Tabaee Damavandi P, Fabin N, Giossi R, Matricardi S, Del Giovane C, Striano P, Meletti S, Brigo F, Trinka E, Lattanzi S. Efficacy and safety of fenfluramine in epilepsy: a systematic review and meta-analysis. Neurol Ther. 2023;12:669\u201386.","journal-title":"Neurol Ther."},{"key":"1936_CR40","unstructured":"European Medicines Agency. Diacomit, INN-stiripentol. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/diacomit-epar-product-information_en.pdf. Accessed Mar 2023."},{"key":"1936_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106646","volume":"174","author":"JJ Halford","year":"2021","unstructured":"Halford JJ, Sperling MR, Arkilo D, Asgharnejad M, Zinger C, Xu R, During M, French JA. A phase 1b\/2a study of soticlestat as adjunctive therapy in participants with developmental and\/or epileptic encephalopathies. Epilepsy Res. 2021;174: 106646.","journal-title":"Epilepsy Res"},{"key":"1936_CR42","unstructured":"European Medicines Agency. Fintepla, INN-fenfluramine. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fintepla-epar-product-information_en.pdf. Accessed Mar 2023."},{"key":"1936_CR43","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56:1246\u201351.","journal-title":"Epilepsia"},{"key":"1936_CR44","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/epi.16546","volume":"61","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Trinka E, Striano P, Zaccara G, Del Giovane C, Nardone R, Silvestrini M, Brigo F. Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia. 2020;61:1090\u20138.","journal-title":"Epilepsia"},{"key":"1936_CR45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","volume":"36","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk A, Schubert-Bast S. A practical guide to the treatment of Dravet syndrome with anti-seizure medication. CNS Drugs. 2022;36:217\u201337.","journal-title":"CNS Drugs"},{"key":"1936_CR46","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","volume":"82","author":"S Lattanzi","year":"2022","unstructured":"Lattanzi S, Trinka E, Zaccara G, Striano P, Russo E, Del Giovane C, Silvestrini M, Brigo F. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs. 2022;82:199\u2013218.","journal-title":"Drugs"},{"issue":"Pt B","key":"1936_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106466","volume":"101","author":"F Brigo","year":"2019","unstructured":"Brigo F, Del Giovane C, Nardone R, Trinka E, Lattanzi S. Intravenous antiepileptic drugs in adults with benzodiazepine-resistant convulsive status epilepticus: a systematic review and network meta-analysis. Epilepsy Behav. 2019;101(Pt B): 106466.","journal-title":"Epilepsy Behav"},{"key":"1936_CR48","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1111\/epi.16366","volume":"60","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi S, Trinka E, Del Giovane C, Nardone R, Silvestrini M, Brigo F. Antiepileptic drug monotherapy for epilepsy in the elderly: a systematic review and network meta-analysis. Epilepsia. 2019;60:2245\u201354.","journal-title":"Epilepsia"},{"key":"1936_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/ane.13025","volume":"139","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi S, Zaccara G, Giovannelli F, Grillo E, Nardone R, Silvestrini M, Trinka E, Brigo F. Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. Acta Neurol Scand. 2019;139:33\u201341.","journal-title":"Acta Neurol Scand"},{"key":"1936_CR50","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/14737175.2020.1801423","volume":"20","author":"A Strzelczyk","year":"2020","unstructured":"Strzelczyk A, Schubert-Bast S. Therapeutic advances in Dravet syndrome: a targeted literature review. Expert Rev Neurother. 2020;20:1065\u201379.","journal-title":"Expert Rev Neurother"},{"key":"1936_CR51","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0140-6736(23)01048-6","volume":"402","author":"AA Asadi-Pooya","year":"2023","unstructured":"Asadi-Pooya AA, Brigo F, Lattanzi S, et al. Adult epilepsy. Lancet. 2023;402:412\u201324.","journal-title":"Lancet"},{"key":"1936_CR52","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/epi.17509","volume":"64","author":"S Matricardi","year":"2023","unstructured":"Matricardi S, Cest\u00e8le S, Trivisano M, Kassabian B, Leroudier N, Vittorini R, et al. Gain of function SCN1A disease-causing variants: Expanding the phenotypic spectrum and functional studies guiding the choice of effective antiseizure medication. Epilepsia. 2023;64:1331\u201347.","journal-title":"Epilepsia"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01936-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01936-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01936-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T16:24:56Z","timestamp":1697559896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01936-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":52,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1936"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01936-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"assertion":[{"value":"24 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 Politecnica delle Marche within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Simona Lattanzi has received speaker\u2019s or consultancy fees from Angelini Pharma, Eisai, GW Pharmaceuticals, and UCB Pharma, and has served on advisory boards for Angelini Pharma, Arvelle Therapeutics, BIAL, Eisai, GW Pharmaceuticals and Rapport Therapeutics outside the submitted work. Eugen Trinka received speaker\u2019s honoraria from UCB Pharma, Biogen, Gerot-Lannach, Bial, Eisai, Takeda, Newbridge, Sunovion Pharmaceuticals Inc., LivaNova and Novartis; consultancy funds from UCB Pharma, Biogen, Gerot-Lannach, Bial, Eisai, Takeda, Newbridge, GW Pharmaceuticals, Sunovion Pharmaceuticals Inc., and Novartis outside the submitted work; and directorship funds from Neuroconsult GmbH. Furthermore, his institution received grants from Biogen, Red Bull, Merck, UCB Pharma, European Union, FWF \u00d6sterreichischer Fond zur Wissenschaftsf\u00f6rderung, and Bundesministerium f\u00fcr Wissenschaft und Forschung. Emilio Russo has received speaker\u2019s fees or funding from, and has participated in advisory boards for, Angelini, Arvelle Therapeutics, Eisai, Kolfarma, Pfizer, GW Pharmaceuticals, UCB Pharma, and Lundbeck outside the submitted work. Sara Matricardi has served on the advisory board for UCB Pharma, and has received consultancy fees from Eisai outside the submitted work. Stefano Meletti received research grant support from the Ministry of Health and the non-profit organization Foundation \u2018Fondazione Cassa di Risparmio di Modena\u2014FCRM\u2019; and has received personal compensation as a scientific advisory board member for UCB and Eisai outside the submitted work. Pasquale Striano received fees and research grants from GW Pharmaceuticals, Zogenyx, Biomarin, and Kolfarma outside the submitted work. Cinzia Del Giovane, Payam Tabaee Damavandi, Mauro Silvestrini, and Francesco Brigo have no conflicts of interest to declare that are directly relevant to the contents of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SL designed and conceptualized the study, carried out the data analyses, and drafted the manuscript. CDG carried out the data analyses. All authors critically revised the manuscript for important intellectual content, approved the final manuscript for submission, and agree to be accountable for all aspects of this work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}